Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Indiana Healthcare Today.
Press releases published on October 16, 2025
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP The CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc …
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has commenced an …
Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025. To …
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after the market close on Thursday, November …
atai Life Sciences Announces Proposed Public Offering of Common Shares
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement …
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression FDA designation follows previously announced Phase 2b topline data which showed …
WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective October 21, 2025
Hangzhou, China, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and …
LifeStance to Host Third Quarter 2025 Earnings Conference Call on November 6, 2025
SCOTTSDALE, Ariz., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter 2025 earnings release before the market opens on …
Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”), the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, joins the digital asset community in celebrating the 14th …
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November …
RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting
ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced it will be featured in …
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell depleting category to receive this …
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide Intention to pursue a Hong Kong initial …
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has demonstrated …
Theriva™ Biologics anuncia una operación de incentivo de warrants por un importe bruto de 4 millones de dólares
ROCKVILLE, Maryland, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en …
Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire
○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2 (n=9)1 ○ Sécurité : en Phase 1 (n=40), lasmé-cel a été …